Investment Rating - The report maintains a "BUY" rating for Xunfei Healthcare, indicating potential returns of over 15% over the next 12 months [12]. Core Insights - Xunfei Healthcare reported FY25 revenue of RMB 915 million, reflecting a year-on-year growth of 24.7%, which was approximately 4% below estimates due to slower G-end growth in the second half of the year [1]. - The G-end growth decelerated significantly from 87% YoY in 1H25 to 4% YoY in 2H25, primarily due to centralized provincial procurement affecting project pricing [1]. - The B-end business showed robust recovery in 2H25, achieving a full-year growth of 31.1% YoY after a weaker first half [1]. - The attributable net loss narrowed by 51.1% YoY to RMB 65 million, driven by improved operating leverage [1]. - The company is focusing on solidifying its G-end leadership, accelerating B-end hospital penetration, and leveraging GBC synergy to develop C-end patient services as a long-term growth engine [1]. Financial Performance - Revenue projections for FY26E, FY27E, and FY28E are RMB 1,119 million, RMB 1,347 million, and RMB 1,599 million respectively, with YoY growth rates of 22.3%, 20.4%, and 18.7% [2]. - The attributable net profit is expected to improve from a loss of RMB 65 million in FY25 to a loss of RMB 40 million in FY26E, narrowing further to RMB 21 million in FY27E, and turning positive with a profit of RMB 3 million in FY28E [2]. - The earnings per share (EPS) is projected to improve from a loss of RMB 0.54 in FY25 to a loss of RMB 0.33 in FY26E, and finally to a profit of RMB 0.03 in FY28E [2]. Market Position and Strategy - Xunfei Healthcare has expanded its client base significantly, serving over 77,000 primary healthcare institutions and 600+ graded hospitals by the end of 2025 [1]. - The company achieved full coverage of its General Practice CDSS across all 90 counties in Zhejiang and secured its first out-of-province imaging cloud platform project in Guangxi [1]. - C-end patient management services revenue increased by 29% YoY to RMB 273 million, accounting for approximately 30% of total revenue, indicating a strategic shift towards a more recurring patient-paid business model [1]. - The communication conversion rate for paying patients reached 50% in 2025, with the Net Promoter Score (NPS) improving from 35% to 50% [1]. Valuation and Target Price - The target price for Xunfei Healthcare has been revised to HK$ 92.55, down from a previous target price of HK$ 143.59, reflecting a 33% upside from the current price of HK$ 69.60 [3]. - The target price is based on a price-to-sales (P/S) ratio of 9x for the 2026 estimates [1].